Philippe Moreau

country of citizenship: France

languages spoken, written or signed: French

occupation: hematologist, university teacher

Series

There is nothing here

Create a new serie

Works

There is nothing here

Create a new work

Articles 361

Date

Title

Authors

2022-03-21

Extramedullary disease in multiple myeloma: a systematic literature review

Artur Jurczyszyn, Jo Caers, Philippe Moreau, Laura Rosiñol
2020-03-23

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

Hareth Nahi, Philippe Moreau, Sebastian Grosicki
2020-04-02

Diagnosis and prognosis are comforted by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study

Philippe Moreau
2020-04-09

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

Athanasios Dimopoulos, Paulo Lucio, Paul G. Richardson, Philippe Moreau, Katja Weisel, Marek Hus, Tsvetan Biyukov, Shien Guo, Sujith Dhanasiri, Larisa Mendeleeva, Nicola Cascavilla, Supratik Basu, Paula Rodríguez-Otero
2020-04-14

Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status

Raphaël Carapito, Eric Spierings, Jürgen Kuball, Didier Blaise, Gerard Socié, Seiamak Bahram, Philippe Moreau, Bronno van der Holt
2020-03-01

Newly Diagnosed Myeloma in 2020

Philippe Moreau
2020-04-21

Timing the initiation of multiple myeloma

Even Holth Rustad, Guy Ledergor, Ferran Nadeu, Nicos Angelopoulos, Thomas Mitchell, Paolo Corradini, Ludmil B. Alexandrov, Xose S. Puente, Elías Campo, Ola Landgren, Peter J Campbell, Francesco Maura, Philippe Moreau, Kenneth C. Anderson, Elli Papaemmanuil
2020-01-02

Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

Alex Minella, Thierry Facon, Philippe Moreau, Michel Attal, Hermann Einsele, Christian Langer
2020-01-22

First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

Joaquin Martinez-Lopez, Jesús San Miguel, Philippe Moreau, Katja Weisel
2020-04-28

Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide

Philippe Moreau
2020-04-29

Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation

Philippe Moreau, Alessandra Di Bacco, Paul G. Richardson
2020-04-30

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

Philippe Moreau, Niels W C J van de Donk
2020-05-05

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes

Laurent Maillet, Philippe Moreau
2020-05-16

Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life

Philippe Moreau
2020-05-15

Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr Virus EBNA-1

Philippe Moreau
2020-05-23

Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma

Zoe Van de Wyngaert, Eric Deconinck, Philippe Moreau
2020-05-23

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

Philippe Moreau, Paul G. Richardson
2020-05-28

FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?

Bastien Jamet, Clément Bailly, Thomas Carlier, Cyrille Touzeau, Philippe Moreau
2020-06-04

ImmunoPET in Multiple Myeloma-What? So What? Now What?

Clément Bailly, Sébastien Gouard, Thomas Carlier, Cyrille Touzeau, Michel Chérel, Philippe Moreau
2020-09-07

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

Athanasios Dimopoulos, Philippe Moreau, Larry D Anderson, Jesús San Miguel, Paul G. Richardson, Teresa Peluso, Tsvetan Biyukov, Alessandro Dal Corso, Pieter Sonneveld, Katja Weisel
2020-09-06

Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials

Elena Zamagni, Thomas Carlier, Clément Bailly, Bastien Jamet, Cyrille Touzeau, Philippe Moreau
2020-12-28

Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma

Fredrik Hellem Schjesvold, Philippe Moreau, Cristina Gasparetto, Shaji K Kumar
2020-12-25

A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia

Pierre Peterlin, Philippe Moreau, Patrice Chevallier, Michel Chérel
2020-01-30

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

G. C. Cook, Jonathan L Kaufman, Jesús San Miguel, Philippe Moreau
2020-02-05

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Ola Landgren, Yael C Cohen, Craig C Hofmeister, Hartmut Goldschmidt, Philippe Moreau, Niels W C J van de Donk
2020-02-20

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses

Philippe Moreau
2020-02-22

Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

Murielle Roussel, Josh Weng, Thierry Facon, Philippe Moreau, Bertrand Arnulf, Margaret Macro, Anne-Marie Stoppa, Benjamin Hebraud, Laurent Garderet, Martine Escoffre-Barbe, Karim Belhadj, Aurore Perrot, Lionel Karlin, Michel Attal, Shien Guo, Sujith Dhanasiri
2020-02-19

Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma

Bastien Jamet, Clément Bailly, Thomas Carlier, Cyrille Touzeau, Mickael Bourgeois, Philippe Moreau
2020-02-24

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

Dan T Vogl, Craig C Hofmeister, David Siegel, Ajay K Nooka, Philippe Moreau, Cristina Gasparetto, David Dingli
2020-02-28

Once-weekly (70 mg/m2 ) vs twice-weekly (56 mg/m2 ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials

Philippe Moreau, Thierry Facon, Robert Z Orlowski, Athanasios Dimopoulos, Anita Zahlten-Kumeli, María Victoria Mateos, Noopur Raje, Khalid Mezzi, Zandra Klippel
2020-03-07

c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma

Alessandra Di Bacco, Peter Ganly, Shaji K Kumar, S. Vincent Rajkumar, Paul G. Richardson, Philippe Moreau
2019-04-25

New insights in the treatment of patients with solitary bone plasmacytoma

Philippe Moreau

Human - wd:Q87734443

Welcome to Inventaire

the library of your friends and communities

learn more